1 / 33

Reduction in Stent Thrombosis – better tablets or better stents?

Reduction in Stent Thrombosis – better tablets or better stents?. Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton. Speaker Fees/Honoraria/Travel Support Lilly/Daiichi Sankyo Schering-Plough The Medicines Company Medtronic Research Support J&J Cordis. MY CONFLICTS

magda
Download Presentation

Reduction in Stent Thrombosis – better tablets or better stents?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Reduction in Stent Thrombosis – better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton

  2. Speaker Fees/Honoraria/Travel Support Lilly/Daiichi Sankyo Schering-Plough The Medicines Company Medtronic Research Support J&J Cordis MY CONFLICTS OF INTEREST ARE

  3. New Generation DES ASA and Oral Anticoag ASA and Ticlopidine ASA and Clopidogrel Prasugrel Ticagrelor % Stent Thrombosis

  4. Risk of Definite Stent Thrombosis Cook, Windecker Circulation 2009

  5. 2.9 % Between 30 days to 3 years Slope = 0.6% / year Late 61 pts (40%) Early 91 pts (60%) N = 152 Patients 0 200 400 600 800 1000 1200 Angiographic DES Stent Thrombosis Bern - Rotterdam Cohort Study N = 8,146 Patients (SES=3875;PES=4271) 3 2 Cumulative probabiity of stent thrombosis (%) Incidence = 1.3/100 pts year 1 0 Days after stent implantation Cumulative Incidence 1.1% 1.2% 1.7% 2.3% 2.9% Wenaweser et al. ESC, Barcelona Sept 2006

  6. Better Drugs?

  7. Discontinuation of thienopyridine therapy:Milan-Siegburg Cohort Study Airoldi F et al Circulation 2007 116:745-54

  8. Stent Thrombosis and 2C19 polymorphisms Mega J et al JAMA 2010, 304(16) 1829-40

  9. Clopidogrel (300 mg) vs. prasugrel (60 mg)Phase I – healthy subjects 100.0 80.0 60.0 Inhibition of Platelet Aggregation (%) 40.0 20.0 0.0 clopidogrel responder clopidogrel non-responder -20.0 Response to clopidogrel Response to prasugrel *Responder =  25% IPA at 4 and 24 h Brandt JT et al. Am Heart J 2007;153:66.e9-e16

  10. 100.0 80.0 60.0 40.0 20.0 0.0 clopidogrel responder clopidogrel non-responder Clopidogrel (300 mg) vs. prasugrel (60 mg)Phase I – healthy subjects Inhibition of Platelet Aggregation (%) -20.0 Response to clopidogrel Response to prasugrel *Responder =  25% IPA at 4 and 24 h Brandt JT et al. Am Heart J 2007;153:66.e9-e16

  11. TRITON-TIMI 38: Stent thrombosis ratesat end of study prasugrel 4 clopidogrel 48% RRR (1.1% ARR) 52% RRR (1.2% ARR) 64% RRR (1.5% ARR) 3 P<0.0001 P<0.0001 P=0.0009 Stent Thrombosis* (%) 2.41 2.35 2 2.31 1 1.27 1.13 0.84 N=6,422 n=2,865 n=2,878 n=3,237 n=3,224 N=6,422 0 All Stents Drug-eluting Stents Bare-metal Stents *Stent thrombosis defined as Academic Research Consortium definite plus probable ARC = Academic Research Consortium ARR = Absolute Risk Reduction HR = Hazard Ratio NNT = Number Needed to Treat PCI = Percutaneous Coronary Intervention RRR = Relative Risk Reduction Wiviott SD et al. Lancet 2008;371:1353-1363

  12. TRITON-TIMI 38: Life Threatening Bleeds at 15 months (All ACS) both + aspirin (n=6,716) (n=6,741) P=0.01 P=NS 1.4% End Point (%) n=85 1.1% 0.9% 0.9% n=64 P=0.002 n=56 n=51 P=NS 0.4% 0.3% 0.3% n=21 0.1% n=19 n=17 n=5 Nonfatal Life Threatening Fatal Intracranial Subsets of Life Threatening Bleeds NS = Not Significant Wiviott SD et al. New Engl J Med 2007;357:2001-2015

  13. Will duration of DAPT be key? • DAPT - 2014 • REAL –LATE - 2011 • OPTIDUAL - 2013

  14. Better Stents?

  15. New stent technologies

  16. Comparative Endothelial Cell CoverageRabbit Denudation Model (14 Days) p=0.05 Express vs. Liberte p=0.001 Express vs. Element EC Strut Coverage (%) (14 Days) Stent Strut Thickness (µm) Express Liberté Element Soucy. EuroPCR 2010

  17. SPIRIT IV

  18. The Abluminal Biodegradable Polymer DES PLA biodegradation and BA9™ elution Abluminal biodegradable coating absorbed after 6-9 months* * In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months - Data on file at Biosensors Intl 19

  19. Leaders Trial - Stent thrombosis

  20. Other Bioabsorbable polymer studies • COSTAR – II • ISAR-TEST 3 • ISAR TEST 4 • NOBORI CORE • NOBORI-I • RESELUTION No reduction ST for DES BP Vs DES PP Salinas P Abs AHA 2010 6032

  21. Genous- E-healing Registryn=4939 Silber S et al, Euro intervention In Press

  22. RES – 1 ( no coating) 200 patients NO ST ? Heparin coating may improve haemocompatability Evolutions of Nevo Stent

  23. Combo Bio-engineered Sirolimus Eluting Stent Granada, et al. CIRC Cardiovasc Interv, June 2010; 3

  24. The Lancet Vol 373 March 14 2009

  25. Absorb: histology and OCT

  26. Clinical trial aiming to demonstrate a reduction in ST from 0.4 to 0.2% 80% power 284,000 subjects! Further studies?

  27. ? Training

  28. THANKYOU

  29. ARC Definitions of ST • Definite Stent Thrombosis • Angiographic or pathological conformation of partial or total thrombotic occlusion within the peri-stent region AND at least one of: • Acute ischaemic symptoms • Ischaemic ECG changes • Elevated biomarkers • Probable Stent Thrombosis • Any unexplained death within 30 days of stent implantation • Any MI related to ischemia in the territory of the implanted stent without angiographic conformation of ST • Possible Stent Thrombosis • Any unexplained death beyond 30 days

More Related